Cargando…

Clarification of Dalfampridine Labeled Indications

Detalles Bibliográficos
Autores principales:	Rabinowicz, Adrian L., Carrazana, Enrique J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2012
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437778/ https://www.ncbi.nlm.nih.gov/pubmed/22380474 http://dx.doi.org/10.18553/jmcp.2012.18.2.156

Ejemplares similares

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Improvement of Intranasal Drug Delivery with Intravail(®) Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System
por: Rabinowicz, Adrian L., et al.
Publicado: (2021)

Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers
por: Madden, Stuart, et al.
Publicado: (2023)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters
por: Cloyd, James, et al.
Publicado: (2021)

Clarification: chemical synergism.
por: Hodgson, E
Publicado: (1995)

Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications
por: Rabinowicz, Adrian L, et al.
Publicado: (2022)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

CATATONIA : NEED FOR CLARIFICATION
por: Andrade, Chittaranjan
Publicado: (1999)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Clarification in the nosology of conduct disorder
por: Raghavan, Jayaprakash
Publicado: (2015)

VetCompanion: response and clarifications
por: Mauer, Matthew Paul, et al.
Publicado: (2017)

Clarification on Islamic Jurisprudence and Transplantation
por: Miller, Andrew C., et al.
Publicado: (2020)

Clarification on viscosity vs. viscoelasticity
por: Oydanich, Marko, et al.
Publicado: (2023)

Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study
por: Hogan, Robert Edward, et al.
Publicado: (2020)

The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters
por: Chung, Steve, et al.
Publicado: (2022)

Use of intranasal rescue therapy for seizure clusters in students with epilepsy: Nurses’ knowledge, perceptions, and practice
por: Santilli, Nancy, et al.
Publicado: (2023)

Some clarifications regarding multiple comparisons
por: Frane, Andrew V.
Publicado: (2016)

Clarification on Pleural Effusions in COVID-19
por: Aujayeb, Avinash
Publicado: (2020)

Some clarifications regarding statistical inference
por: Frane, Andrew V.
Publicado: (2022)

Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study
por: Sperling, Michael R., et al.
Publicado: (2022)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL‐1 to Healthy Volunteers
por: Tanimoto, Sarina, et al.
Publicado: (2020)

Clarification on Rotation Rates of Textured Breast Implants
por: Wixtrom, Roger N., et al.
Publicado: (2015)

Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study
por: Tarquinio, Daniel, et al.
Publicado: (2023)

Treatment of Seizure Clusters in Epilepsy: A Narrative Review on Rescue Therapies
por: Becker, Danielle A., et al.
Publicado: (2023)

Clarification
Publicado: (2007)

Clarification
Publicado: (2009)

Clarification
Publicado: (2013)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39ubm59cgjrvqjemskldmc95oc